Metabolic Research

Orforglipron

FDA-approved product existsWeight & metabolic
5.8/10

BioHarmony verdict

Worth trying

Orforglipron (Foundayo) is the first FDA-approved non-peptide oral GLP-1 pill, cleared for obesity in April 2026. It cut body weight about 11.2 percent at 72 weeks in the ATTAIN-1 Phase 3 trial, less than the injectables but with once-daily oral convenience and no food or water restrictions.

Read full report

What is Orforglipron?

Orforglipron, sold as Foundayo, is the first non-peptide GLP-1 receptor agonist you can swallow as a daily pill, and that one fact is the whole reason it matters. Every other GLP-1 drug that works well, semaglutide and tirzepatide, is a peptide that stomach enzymes would shred, so it has to be injected or, in oral semaglutide's case, wrapped in a fussy absorption trick. Orforglipron is a small molecule. Enzymes leave it alone, it absorbs at roughly 79 percent, and you take it any time of day with or without food.

From the BioHarmony report, reviewed 2026-09-08.

Safety watch-outs

  • Severe, persistent abdominal pain, possibly radiating to the back (possible pancreatitis): stop and seek care immediately.
  • A lump or swelling in the neck, hoarseness, or trouble swallowing (thyroid warning): stop and consult a clinician.
  • Personal or family history of medullary thyroid cancer or MEN2: do not use.
  • Repeated vomiting or signs of dehydration during titration: pause and reassess the dose with a clinician.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Orforglipron yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingApproved product exists; compounded copies are not FDA approved
Last checked2026-09-02
Next review2026-10-02 (overdue, details paused)

Primary sources

Sources are still being reviewed for this compound.

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.